Bookmark
Forward
QuickView for omalizumab (compound)
PubChem Substance
| Name: | omalizumab |
|---|---|
| PubChem Substance ID: | 3820420 |
| Synonyms: |
Immunoglobulin G, anti-(human immunoglobin E FC region) (human-mouse monoclonal E25 clone PSVIE26 gamma-chain), disulfide with human-mouse monoclonal E25 clone PSVIE26 kappa-chain, dimer; Omalizumab; Xolair; 242138-07-4
|
DrugBank
Identification
| Name: | omalizumab |
|---|---|
| Name (isomeric): | DB00043 |
| Drug Type: | biotech |
| Synonyms: |
Ig gamma-1 chain C region
|
| Brand: | Xolair (Genentech Inc) |
| Category: | Immunomodulatory Agents, Anti-Asthmatic Agents |
| CAS number: | 242138-07-4 |
Pharmacology
| Indication: | For treatment of asthma caused by allergies |
|---|---|
| Pharmacology: | Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma. |
| Mechanism of Action: | Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils. |
| Biotransformation: | Most likely removed by opsonization via the reticuloendothelial system. |
| Route of elimination: | Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile. |
| Half Life: | 26 days |
| Affected organisms: | Humans and other mammals |
Targets
